FONAR reported QQ3 2024 revenue of $25.718 million, up modestly on a year-over-year basis and sequentially, with a gross margin of 45.7%. The quarter delivered EBITDA of $6.02 million and operating income of $3.75 million, yielding a net income of $1.87 million and basic earnings per share of $0.28. The company maintained solid liquidity, ending the period with about $53.98 million in cash and cash equivalents and a net cash position (net debt negative) of roughly $13.08 million after accounting for long-term and short-term borrowings. Operationally, FONAR generated positive cash flow from operations of $2.86 million and free cash flow of about $2.68 million, supporting a resilient balance sheet despite a relatively small revenue base in the Medical Equipment and Diagnostic services segments. Valuation metrics remain modestly favorable, with a price-to-book around 0.78 and a price-to-earnings near 17x, reflecting a small-cap healthcare exposure with substantial cash versus modest near-term top-line growth potential. Management commentary is not included in the provided transcript data for QQ3 2024, limiting the ability to quote direct remarks from the earnings call. Investors should monitor quarterly receivables dynamics, given an elevated Days Sales Outstanding profile, as well as ongoing reimbursement and market adoption trends for upright MRI technology.